Form 4: Harvard Bioscience Director Awarded 110,000 Restricted Stock Units

Harvard Bioscience Director Seth Benjamin Benson was awarded 110,000 restricted stock units, vesting by July 2026.

Summary

• Director Seth Benjamin Benson of Harvard Bioscience Inc. (HBIO) was granted 110,000 shares of common stock.
• The transaction date for this award was July 16, 2025.
• These shares represent restricted stock units (RSUs) with an acquisition price of $0.00 per share, indicating an equity award rather than a cash purchase.
• Following this transaction, Mr. Benson beneficially owns 110,000 shares directly.
• The RSUs will fully vest on the earlier of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, or July 16, 2026.

Sentiment

Score: 7

Explanation: The filing reports a standard equity award to a director, which is generally a positive sign of alignment and retention, but does not contain new financial performance data.

Positives

• The award of restricted stock units to a director aligns their interests with long-term shareholder value.
• The grant of 110,000 RSUs indicates continued commitment and incentivization for the director.

Risks

• The ultimate value of the restricted stock units is subject to the future performance of Harvard Bioscience Inc.'s stock price until vesting.

Future Outlook

The restricted stock units are designed to incentivize the director for future performance, with vesting tied to future dates and potentially the company's next annual meeting.

Industry Context

Equity awards like restricted stock units are a common form of executive and director compensation in the biotechnology and life sciences industry, aligning management incentives with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation, particularly through restricted stock units, is a standard practice across publicly traded companies, including those in the life sciences sector like Thermo Fisher Scientific, Danaher Corporation, or Agilent Technologies, to retain and incentivize key personnel.
• The specific size of the award (110,000 RSUs) would need to be compared against similar director awards at companies of comparable market capitalization and revenue within the biotech/life sciences tools industry to assess its relative scale.

Corporate Governance

Related Party Transactions

• The award of 110,000 restricted stock units to Director Seth Benjamin Benson constitutes a related party transaction in the context of director compensation.

Stakeholder Impact

• Shareholders: The award aligns the director's interests with shareholders by tying compensation to future stock performance, potentially fostering long-term value creation.

Next Steps

• The restricted stock units will vest on the earlier of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity award to an existing director, which is a positive for aligning interests but does not provide new fundamental financial data to warrant a change in investment recommendation. It is a standard compensation event.

Keywords

Harvard Bioscience, HBIO, Restricted Stock Units, RSU, Director Compensation, Equity Award, Insider Transaction, Form 4